ASH: A cell therapy startup with roots in Irv Weissman's lab nearly wipes out a chronic side effect in early trials

Nicole DeFeudis

Editor

While a hematopoietic stem cell transplant is the best option for some patients with blood cancer, the procedure can lead to dangerous complications, such as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ASH: A cell therapy startup with roots in Irv Weissman's lab nearly wipes out a chronic side effect in early trials

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

ASH: A cell ther­a­py start­up with roots in Irv Weiss­man­'s lab near­ly wipes out a chron­ic side ef­fect in ear­ly tri­als

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

ASH: A cell therapy startup with roots in Irv Weissman's lab nearly wipes out a chronic side effect in early trials